Becton, Dickinson and Company (BDX) to Issue Quarterly Dividend of $1.05 on March 31st

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Tuesday, January 27th. Investors of record on Tuesday, March 10th will be paid a dividend of 1.05 per share by the medical instruments supplier on Tuesday, March 31st. This represents a c) dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th.

Becton, Dickinson and Company has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Becton, Dickinson and Company to earn $15.64 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 26.9%.

Becton, Dickinson and Company Stock Down 0.8%

BDX opened at $201.81 on Thursday. The stock’s 50 day moving average price is $198.08 and its 200 day moving average price is $190.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The stock has a market cap of $57.50 billion, a P/E ratio of 34.62, a P/E/G ratio of 2.25 and a beta of 0.23. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The company had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on BDX. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada upped their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 17th. Piper Sandler lifted their price target on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Bank of America upped their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $209.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.